A Randomized Prospective Trial Comparing Low-volume Bowel Preparation Methods

Sponsor
Korea University Anam Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT02250196
Collaborator
(none)
200
1
2
8
24.8

Study Details

Study Description

Brief Summary

Colonoscopy is a common screening method to detect polyps and CRC. With the early detection of CRC through screening colonoscopy, patients could have better therapeutic effects and outcomes. In population screening programs, an increase in completed colonoscopies is related to a decrease in mortality from CRC. However, the miss rate for detecting colorectal neoplastic polyps of colonoscopy is 5-28%. The reluctance of participants to undergo bowel preparation results in the relatively low rate of detection of polyps and CRC, because poor preparation interferes with successful colon mucosa examination during a colonoscopy.

Low-volume bowel preparations provide equivalent cleansing effect compared with standard 4 liter polyethylene glycol. However, studies comparing the superiority between low-volume bowel preparations are rare, and results are controversial. This study aimed to compare the bowel cleansing quality and tolerability between split-dose sodium picosulfate/magnesium citrate and polyethylene glycol with ascorbic acid.

Condition or Disease Intervention/Treatment Phase
Phase 3

Detailed Description

  1. Study design: endoscopist-blinded, prospective, randomized controlled trial

  2. Subjects

  3. Entry criteria: Male or female patients, aged between18 and 80 years undergoing elective outpatient colonoscopy were eligible for the study.

  4. Exclusion criteria:

patients who had chronic kidney disease, severe heart failure(New York Heart Association [NYHA] class III or IV), uncontrolled hypertension (systolic pressure ≥170 mm Hg, diastolic pressure ≥100 mm Hg), severe constipation, any bowel resection, significant gastroparesis, or suspected bowel obstruction or perforation.

  1. Sampling design: Consecutive recruitment of consenting patients

  2. Variables Predictor

  3. group 1 (SPMC 2) received one sachet of SPMC at 7 p.m the evening before colonoscopy and another sachet of SPMC at 5 hours before procedure

  4. group 2 (PEG-Asc) received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure;

  5. Primary Outcome: Quality of bowel preparation (Boston Bowel Preparation Scale, Aronchick scale, bubble score)

  6. Secondary Outcome: Tolerability, palatability

Study Design

Study Type:
Interventional
Actual Enrollment :
200 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Investigator)
Primary Purpose:
Supportive Care
Official Title:
A Randomized, Prospective Tiral on Efficacy and Tolerability of Low-volume Bowel Preparation Methods for Colonoscopy
Study Start Date :
Mar 1, 2013
Actual Primary Completion Date :
Sep 1, 2013
Actual Study Completion Date :
Nov 1, 2013

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: PEG-Asc

group 1 (PEG-Asc, N=100) received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure

Drug: PEG-Asc
received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure
Other Names:
  • Coolprep®; TaeJoon Pharmaceuticals, Seoul, Korea
  • Active Comparator: SPMC 2

    group 2 (SPMC 2, N=100) received one sachet of SPMC at 7 p.m the evening before colonoscopy and another sachet of SPMC at 5 hours before procedure

    Drug: SPMC 2
    received one sachet of SPMC at 7 p.m the evening before colonoscopy and another sachet of SPMC at 5 hours before procedure
    Other Names:
  • Picolight(Pharmbio korea, Seoul, Korea)
  • Outcome Measures

    Primary Outcome Measures

    1. the quality of the bowel preparation using Preparation Scale [20 minutes]

      Preparation Scale

    Secondary Outcome Measures

    1. Completeness of the bowel preparation [30 minutes before the colonoscopy]

      Patient compliance was recorded by checking the completeness of the prescribed preparation methods including bowel cleansing agent solution and recommended clear liquid.

    2. the patient's tolerability [30 minutes before the colonoscopy]

      Patients were asked with questionnaires about the symptoms associated with the preparation to assess the patients' tolerability before the colonoscopy. Patients were asked whether they experienced any of the following : abdominal fullness, cramping, nausea, vomiting, sleep disturbance, and overall discomfort, and these symptoms were scored on a 5-point scale where 1 = "none", 2 = "mild", 3 = "moderate", 4 = "severe", and 5 = "very severe".

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Male or female patients, aged between18 and 80 years undergoing elective outpatient colonoscopy were eligible for the study
    Exclusion Criteria:
    • patients who had chronic kidney disease, severe heart failure(New York Heart Association [NYHA] class III or IV), uncontrolled hypertension (systolic pressure ≥170 mm Hg, diastolic pressure ≥100 mm Hg), severe constipation, any bowel resection, significant gastroparesis, or suspected bowel obstruction or perforation.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Korea University Anam Hospital Seoul Anamdong 5-ga, Seongbuk-gu Korea, Republic of 136-705

    Sponsors and Collaborators

    • Korea University Anam Hospital

    Investigators

    • Study Director: Eun Sun Kim, PhD, Division of Gastroenterology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea
    • Principal Investigator: In Kyung Yoo, MD, Division of Gastroenterology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    In-Kyung Yoo, fellow, Korea University Anam Hospital
    ClinicalTrials.gov Identifier:
    NCT02250196
    Other Study ID Numbers:
    • Korea University Prep
    First Posted:
    Sep 26, 2014
    Last Update Posted:
    Sep 26, 2014
    Last Verified:
    Sep 1, 2014
    Keywords provided by In-Kyung Yoo, fellow, Korea University Anam Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 26, 2014